Pharvaris To Present at the APAAACI 2023 International Conference
13 Outubro 2023 - 7:50AM
Pharvaris (Nasdaq: PHVS), a clinical-stage company developing
novel, oral bradykinin B2 receptor antagonists to treat and prevent
hereditary angioedema (HAE) attacks, today announced the acceptance
of an abstract oral presentation at the Asia Pacific Association of
Allergy, Asthma, and Clinical Immunology (APAAACI) and Allergy and
Clinical Immunology Society of Singapore (ACIS) APAAACI 2023
International Conference, to be held from October 23-26, 2023, at
the Suntec Singapore International Convention and Exhibition Center
in Singapore.
Presentation details:
- Title: Bradykinin B2 receptor antagonist
deucrictibant immediate-release capsule for treatment of HAE
attacks: Phase 2 resultsPresenter: Marcus Maurer,
M.D. Date/Time: Monday, October 23, 11:20-11:30
a.m. SGT (Sunday, October 22, 11:20-11:30 p.m. EDT)
Following the close of the session, the slide presentation will
be made available on the Investors section of the Pharvaris website
at: https://ir.pharvaris.com/news-events/events-presentations.
About PharvarisBuilding on its deep-seated
roots in HAE, Pharvaris is a clinical-stage company developing
novel, oral bradykinin B2 receptor antagonists to treat and prevent
HAE attacks. By directly pursuing this clinically proven
therapeutic target with novel small molecules, the Pharvaris team
aspires to offer people with all sub-types of HAE efficacious,
safe, and easy-to-administer alternatives to treat attacks, both
on-demand and prophylactically. The company brings together the
best talent in the industry with deep expertise in rare diseases
and HAE. For more information, visit https://pharvaris.com/.
Contact
Maggie Beller
Executive Director, Head of External and Internal Communications
Maggie.beller@pharvaris.com
Pharvaris NV (NASDAQ:PHVS)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Pharvaris NV (NASDAQ:PHVS)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024